You just read:

REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

News provided by

REGENXBIO Inc.

Oct 11, 2019, 19:15 ET